Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study

BACKGROUND: The role of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) induction coupled with standard concurrent chemoradiotherapy (CRT) is unclear in unresectable, stage III, EGFR-mutant non-small-cell lung cancer (NSCLC). Therefore, a phase II trial was conducted to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotta, K., Saeki, S., Yamaguchi, M., Harada, D., Bessho, A., Tanaka, K., Inoue, K., Gemba, K., Shiojiri, M., Kato, Y., Ninomiya, T., Kubo, T., Kishimoto, J., Shioyama, Y., Katsui, K., Sasaki, J., Kiura, K., Sugio, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233144/
https://www.ncbi.nlm.nih.gov/pubmed/34153652
http://dx.doi.org/10.1016/j.esmoop.2021.100191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233144/
https://www.ncbi.nlm.nih.gov/pubmed/34153652
http://dx.doi.org/10.1016/j.esmoop.2021.100191

Ejemplares similares